載入...

The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control

BACKGROUND: iGlarLixi is an injectable combination of long acting insulin glargine (iGlar) and glucagon-like peptide 1 receptor agonist lixisenatide in a fixed ratio, which was proven safe and effective for the treatment of type 2 diabetes. Lixisenatide and iGlar act differently on fasting and postp...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Diabetes Sci Technol
Main Authors: Gautier, Thibault, Umpierrez, Guillermo, Renard, Eric, Kovatchev, Boris
格式: Artigo
語言:Inglês
出版: SAGE Publications 2019
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256059/
https://ncbi.nlm.nih.gov/pubmed/31810389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296819891170
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!